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Abstract
Background: Febrile neutropenia (FN) is a common infectious complication in chemotherapy. The mortality of FN
is higher in hematologic malignancy patients, and early diagnostic marker is needed. Presepsin is a prompt and
specific marker for bacterial sepsis, but its efficacy in severe febrile neutropenia (FN) is not well confirmed. We tried
to clarify whether it is a useful maker for early diagnosis of FN in patients during massive chemotherapy.
Methods: We measured plasma presepsin levels every 2–3 day in FN cases and evaluated its change during the
course of massive chemotherapy. The patients had hematologic malignancy or bone marrow failure, and in all
cases, neutropenia was severe during the episode. The baseline levels, onset levels, increase rate at FN onset, and
onset / baseline ratio were evaluated for their efficacy of early FN diagnosis.
Results: Eleven episodes of bacteremia (six gram negatives and five gram positives) in severe neutropenia were
analyzed in detail. While plasma presepsin level was strongly associated to the CRP level (r = 0.61, p < 0.01), it was
not associated with the absolute WBC count (r = −0.19, p = 0.19), absolute neutrophil count (r = −0.11, p = 0.41) or
absolute monocyte count (r = −0.12, p = 0.40). The average of onset presepsin level was 638 ± 437 pg/mL and the
cutoff value (314 pg/mL) has detected FN onset in 9 of 11 cases. The two cases undetected by presepsin were
both Bacillus species bacteremia.
Conclusions: Plasma presepsin level is a reliable marker of FN even in massive chemotherapy with very low white
blood cell counts. Closer monitoring of this molecule could be a help for early diagnosis in FN. But bacteremia
caused by Bacillus species was an exception in our study.
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Background
Patients with hematologic malignancies often suffer from
severe infections. The malignancies themselves are disor-
ders of immune systems, and chemotherapy further
causes febrile neutropenia (FN). Some patients die of in-
fection in spite of immediate antimicrobial treatment. In
acute myeloid leukemia, for example, the incidence of
chemotherapy associated infectious toxicities is as high
as 64%, and the mortality is higher than 10% [1]. There
have been many approaches, including biomarkers, to
improve the prognosis of FN. But still, it is difficult to
predict or to detect those malicious events in the
earliest time.
Presepsin (soluble CD14 subtype) is a novel biomarker
of sepsis. It is useful in early diagnosis, and it can also be
a prognostic marker of severe sepsis [2–6].
While this molecule is a prompt and specific marker
for bacterial infections, its reliability in FN is not yet
confirmed. Especially, massive chempotherapy causes
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severe cytopenia including CD14 expressing neutrophils
or monocytes. Because presepsin derives from CD14 [7],
severe neutropenia can cause false-negativity of this
molecule.
Thus, we conducted a simple study of plasma presep-
sin measurements to find answer to two practical
questions;
1) Does presepsin rise in bacteremia cases even in the
setting of severe neutropenia?




This study was conducted in Shiga University of Medical
Science Hospital, from May 2014 to October 2014.
During the period, plasma samples were collected
from hematologic malignancy and bone marrow failure
patients under chemotherapy. The patients received
conventional induction chemotherapy or hematopoietic
stem cell transplantation (HSCT) and all of them experi-
enced severe neutropenia.
We evaluated the plasma presepsin levels in febrile
neutropenia group (FN group). And we compared the
values with those of control cases, afebrile neutropenia
group (AFN group).
We defined two groups as follows;
1) FN group patients are those diagnosed of bacteremia
during neutropenic period (WBC count less than
1,000/μL or neutrophil count less than 500 /μL).
Pathogens were identified in blood cultures and
patients were treated with appropriate antimicrobial
therapy.
2) AFN group patients were those who had no
febrile episodes for 3 weeks after chemotherapy.
They received no antimicrobials during the course.
Plasma presepsin level measurement
We made regular blood examination every 2–3 day (ap-
proximately on days 1,3,5,8,10,12 and 15) of chemother-
apy. After centrifugation within 2 h after phlebotomy,
the plasma was preserved in −80 °C till measurement.
Plasma presepsin level was measured by a rapid chemilu-
minescent enzyme immunoassay on the fully automated
PATHFAST® immunoanalyzer (Mitsubishi Chemical Medi-
ence Corporation, Tokyo, Japan) [8]. We defined the cut-off
value 314 pg/mL according to manufacturer’s instruction.
Evaluation
We evaluated serial change in plasma presepsin levels at
regular intervals.
Specifically, the value obtained on day −1 to 1 of
chemotherapy was defined as baseline level. We defined
the first day of fever onset (≥38.0 °C) as the “onset day”.
Blood culture was routinely obtained within ±1 day of
fever onset.
The “onset plasma presepsin level (onset level)” was
defined as the result on the day of fever and blood cul-
ture positivity.
And the presepsin increase rate (IR) was defined as
IR %ð Þ ¼ onset levelð Þ‐ previous levelð Þf g= previous levelð Þ  100
Blood examination interval
The onset levels within one episode, presepsin IR
around the day of febrile neutropenia onset, and onset /
baseline ratio were evaluated.
Statistical analysis
We performed Student’s t-test for comparisons of two
independent groups of sampled data. The data were
expressed as mean ± standard deviation. P values of
<0.05 were considered evidence of a significant
difference.
The linear dependence between the two variables was
assessed by Pearson’s product–moment coefficient. R
and Rho values ≥0.7 were considered to define a strong
correlation between variables, respectively. And R and
Rho ranging between 0.69 and 0.5 and 0.49 to 0.3 were
considered to define moderate and low correlation,
respectively.
We analyzed data using the statistical software JMP®
10 (SAS Institute Inc., Cary, NC, USA).
Results
Patient background (Table 1)
Table 1 shows the patient characteristics.
There were five myeloid diseases, including three acute
myeloid leukemia (AML), 1 myelodysplastic syndrome
(MDS) RAEB2, and 1 severe aplastic anemia (AA).
Other five cases were lymphoid diseases, including
two malignant lymphoma (ML), two multiple myeloma
(MM), and one acute lymphoid leukemia (ALL).
All the cases were on chemotherapy; six on induction
therapy, three on myeloablative conditioning regimen
for hematopoietic stem cell transplantation, and one on
consolidation therapy. All the regimens had potentials of
severe myelosuppression.
The Nadir WBC count during the chemotherapy was
0–100/μL in nine out of ten cases. There were no cases
with severe renal failure.
Episodes of febrile neutropenia (Table 1)
Eleven episodes of febrile neutropenia were observed in
ten patients; 9 with primary bacteremia, 1 with severe
pneumonia, and 1 with skin & soft tissue infection.
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Pathogens identified in blood cultures were, six gram
negative bacteria (3 Klebsiella pneumoniae, 1 Escherichia
coli, 1 Enterobacter aerogenes, and 1 Bacteroides fragilis)
and five gram positive bacteria (1 Staphylococcus epider-
midis, 1 Staphylococcus hominis, 1 Bacillus cereus, 1
Bacillus sp., and 1 Enterococcus gallinarum).
The onset of infection was on the day 11.9 (average,
range [3–18]) of chemotherapy, and 6.5 (average, range
[4–9]) samples per one case were examined for plasma
presepsin level.
All FN patients survived bacteremia after receiving
appropriate antimicrobial agents, though one case had
severe acute respiratory distress syndrome requiring in-
tensive care.
Change of plasma presepsin levels in FN cases
Figure 1 shows the changes in plasma presepsin level
over time during a chemotherapy course. All the sam-
ples measured in this study are plotted in the figure.
The average of presepsin levels in myeloid diseases
(384 ± 369.9 pg/mL was slightly lower than that of
lymphoid diseases (384 ± 369.9 557 ± 493.5pg/mL, p
= 0.11, Student’s t-test).
There was no significant decrease within the first week
of chemotherapy, which usually causes severe neutropenia.
The lowest value was 82.6 pg/mL scored in case 8, a
multiple myeloma case, on day 8 of HSCT conditioning
regimen. On that day, the patient was afebrile with
WBC count of 100/μL, but 4 days later, he developed
bacteremia with presepsin level of 503 pg/mL. The de-
tailed trend of presepsin and CRP levels are shown in
Additional file 1: Table S1.
Plasma presepsin levels and other parameters
Figure 2a shows the relationship between plasma presep-
sin level and white blood cell count (WBC).
Plasma presepsin level was not significantly associated
with the absolute WBC count (r = −0.19, p = 0.19).
The median plasma presepsin level was 456.5 pg/mL
in low WBC count below 100 /μL.
The plasma presepsin level was not associated with ab-
solute neutrophil count (r = −0.11, p = 0.41) or absolute
monocyte count (r = −0.12, p = 0.40), either. Meanwhile,
plasma presepsin level was strongly associated to the
CRP level (r = 0.61, p < 0.01, Fig. 2b.)
We also examined the association between presepsin
levels and renal function.
The plasma presepsin level was not associated with
serum creatitine level (r = 0.08, p = 0.55), or estimated
glomerular filtration rate (eGFR) (r = 0.21, p = 0.12).
Baseline, onset plasma presepsin levels and increase
rates in FN cases
Onset levels, increase rates (IR) and onset / baseline
ratio of presepsin are shown in Table 2
The average baseline level was 220 ± 83.1 (range
106–333) pg/mL and average onset level was 638 ± 437
(range 217–1810) pg/mL.
In the episodes with gram negative bacteremia, onset
levels were elevated beyond cut-off level in all cases
(average 819 ± 520 pg/mL, range 341–1810 pg/mL).
In the episodes with gram positive bacteremia, on-
set levels were elevated in 3 out of 5 cases (average
420 ± 97.0 pg/mL, range 217–644 pg/mL). The onset
presepsin levels are slightly higher in gram negative
bacteremia than gram positive bactermia (p = 0.14,
Student’s t-test). Two cases of Bacillus bacteremia
(case 10,11) showed no elevation of onset presepsin
levels at the onset time.
Table 1 Patient characteristics
Comorbidities Acute myeloid leukemia 3
multiple myeloma 2
malignant lymphoma 2
acute lymphoid leukemia 1
myelodysplastic syndrome 1
aplastic anemia 1











focus of infectiona primary bacteremia 9
severe pneumonia 1
skin & soft tissue infection 1












days of the infection onsetb 11.9 [3–18]
average number of the samples
examined for presepsin
6.5 [4–9]
afocus denotes the entry site of bacteremia
bday 1 is defined as the day when chemotherapy regimen starts
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The average increase rate (IR) was 44 (range 1–112) %
and, nine out of 11 bacteremic FN cases showed IR of
more than 30%.
When we apply onset value ≥ 314 pg/mL and/or IR
larger than 30% as positive findings, we could detect 10
out of 11 febrile neutropenia cases.
Or, onset / baseline ratio above two has detected 10
out of 11 cases.
Presepsin levels in representative cases
We show representative FN cases, demonstrating the efficacy
of plasma presepsin levels in early diagnosis of septicemia.
Case 3 (Fig. 3a) shows typical clinical course of gram
negative bacteremia in a case with B cell lineage acute
lymphoid leukemia. The onset of febrile neutropenia was
on day 10 of consolidation therapy. On day 9, presepsin
was elevated to 558 pg/mL while CRP was within nor-
mal range at the same time. The blood culture on day
10 has detected K.pneumoniae.
Case 4 (Fig. 3b) shows the dynamics of presepsin levels
in MDS case. On day 1 of chemotherapy, presepsin level
was not elevated in spite of marked leukocytosis and
tumor fever. On day 5, presepsin elevated and cefepime
was started, and on day 8, the patient developed methicil-
lin resistant S.hominis bacteremia. Probably the elevation
of presepsin suggested uncontrolled bacteremia with the
organism resistant to cefepime. Meropenem and
vancomycin was started, and soon the fever has sub-
sided, accompanied by presepsin level decrease. One
day after cessation of antibiotics, the case developed
high fever due to K. pneumoniae bacteremia. Presepsin
was measured 6 h prior to fever and chills, and was
Fig. 1 Plasma presepsin level change over time and comorbidities. Changes in plasma presepsin level over time in lymphoid malignancy cases
(a) and myeloid malignancy cases (b) are shown. Horizontal axis shows the day of chemotherapy. The average of plasma presepsin level was
lower in myeloid malignancies. Note that most of the presepsin values are above 100 pg/mL, suggesting that it maintains certain levels even in
severe neutropenic state
Fig. 2 Plasma presepsin levels and other parameters measured at
the same time point. a Plasma presepsin levels white blood cell
count. White blood cell count and plasma presepsin levels were
plotted. Plasma presepsin levels were not significantly associated to
the absolute white blood cell count(r=−0.19, p= 0.19). Plasma presepsin
level was not associated with neutrophil count, or monocyte count,
either (data not shown). b Plasma presepsin levels and C-reactive protein
(CRP) levels. CRP levels and plasma presepsin levels were plotted.
Plasma presepsin levels were strongly associated to the CRP levels.
(r = 0.61, p < 0.01)
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elevated again, suggesting the ability to detect infec-
tion even in an asymptomatic state. After appropriate
antibiotic treatment, presepsin level was normalized
again. Meanwhile, neutrophil count was below 600/μL.
A few days after resolution, the temperature has risen
again with erythema nodosa,but presepsin level was
within normal range.
In cases of Bacillus sp., plasma presepsin level was not
elevated at the onset of febrile neutropenia. In both
cases, presepsin level was elevated 2 days after the onset.
Case 10 is the aplastic anemia patient in HSCT. He suf-
fered from Bacillus bacteremia as blood stream infection.
The onset of FN was on day 3 of chemotherapy. The
presepsin level was within normal range on the onset
day, but 2 days later, it has increased to 325 pg/mL. Case
11 was AML patient on induction chemotherapy. On
day 18, she developed bacteremia and severe meningitis.
But presepsin level was 217 pg/mL. Two days later, it
showed an increase to 685 pg/mL.
Presepsin levels of AFN cases in comparison to FN cases
Table 2 shows the result of parameters in AFN cases. As
for AFN cases, the average of baseline plasma presepsin
levels was 120 ± 52.5 pg/mL. There was no drastic
decrease during the severe neutropenic period and none
of the values was above the cut off level.
The average of all examined presepsin levels in AFN
group (n = 25) was 162 ± 61.7 pg/mL, and it was signifi-
cantly lower than that of FN group (n = 69) (451 ±
304 pg/mL, p = 0.0012).
The highest levels in AFN cases were also compared
with onset plasma presepsin levels of FN group.
The average of the highest presepsin levels was 239 ±
46.2 pg/mL in AFN cases. It was slightly lower than in
FN cases (638 ± 437 pg/mL, p = 0.099, Student’s t-test).
Discussion
Presepsin is a one of the subtypes of soluble N-terminal
fragment of CD14 protein with molecular weight of
13 kDa. It is the receptor for lipopolysaccharide (LPS) /
LPS –binding protein complexes [2] and is released in
the early phase of infection. The molecule rises as early
as within 2 h of inflammation onset, which is even earl-
ier than procalcitonin, C-reactive protein (CRP) or
interleukin-6 [2, 9]. Another fascinating aspect of pre-
spsin is its high specificity for bacterial infections. Be-
cause its precursor CD14, expressed on the surface of
phagocytes, is internalized during bacterial phagocytosis,
Fig. 3 Plasma presepsin levels in representative cases. a Case 3; 48 year old male with B-ALL, undergoing “JALSG Ph(−) B-ALL 213 consolidation”
chemotherapy. He experienced K.pneumoniae bacteremia on day 10. WBC count was 200/mL and plasma presepsin level was already elevated
one day prior FN onset. CRP was not elevated at this time. b Case 4; 68 year old female with MDS and Sweet disease, undergoing induction
chemotherapy (MEC-GO). Plasma presepsin level was not elevated in spite of marked leukocytosis (day1) or non-infectious fever caused by
erythema nodosa (day24). It was elevated at the onset of S.hominis bacteremia (day8), and at K.pneumoniae bacteremia (day15)
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the processed subtype presepsin has strong association
with bacterial infections. Nowadays, it is well known that
presepsin is a useful early diagnostic marker of sepsis.
And there are reports showing its superiority to CRP in
differentiating bacteremic SIRS from that of other causes
[10]. Its diagnostic efficacy has been proved in various
fields such as surgery, burn, neonates, and central nervous
system [11–14]. However, the reliability of presepsin in fe-
brile neutropenia has not been well demonstrated so far.
Probably the fact that CD14 is expressed in neutrophils or
monocytes, might pose a question against its quality, espe-
cially in a severe neutropenia after massive chemotherapy.
Our study is one of the first reports showing dynamics
of plasma presepsin levels in FN cases. And we proved
that 1) presepsin maintains a proper level in severe neu-
tropenia cases, and 2) presepsin is a useful marker for
early diagnosis of FN.
The most important finding in this study is that pre-
sepsin level was not associated with WBC, neutrophil,
or monocyte count. The baseline and the lowest plasma
presepsin levels were not extremely low as expected
even in neutropenia settings. Giavarina et. al. [15] stud-
ied the presepsin levels of healthy adult controls, con-
cluding that the reference limits for the presepsin were
55–184 pg/mL (90% confidence intervals, CI, were 45 to
58 and 161 to 214, respectively). The lowest value in our
study was 48.7 pg/mL (AFN group), which is not so low
compared with those reference data. Thus we can say
that presepsin maintains a proper level even in severe
neutropenia cases. It might be explained by the recent
finding that monocyte, rather than neutrophil, is the
dominant producer of presepsin [16]. Production from
tissue macrophages or resident monocytes might play a
role in maintaining the plasma presepsin level.
Another result is that plasma presepsin level was sig-
nificantly elevated at the early phase of most bacteremia
episodes. The data have shown a clear relationship be-
tween presepsin level and CRP, suggesting its sensitivity
and validity in evaluation of infection. Especially in gram
negative bacteremia, it was higher than the normal range
in all the cases. Various cutoff levels of presepsin has
been proposed to detect bacterial infection, but in those
reports, the background of the cases (Intensive care
units, emergency room, or general medicine), and goals
of the studies (discrimination of bacterial/non bacterial
infection, or early detection of sepsis) are different. We
simply applied the cutoff level as written in the manu-
facturer’s instruction. The cutoff value of 314 pg/mL
was lower than some of the reports [2–6]. We aimed to
improve sensitivity rather than specificity because our
goal is to detect the FN onset in the early phase and to
prevent overt sepsis. However, in the two FN bacteremia
cases caused by Bacillus species, presepsin level stayed
within the normal range at the onset day. We could say
presepsin level is not appropriate to detect early phase
of Bacillus bacteremia, though the reason cannot be
readily explained. Probably it might be due to the low
immunogenicity by this bacterium.
The size of this study was small, and retrospective de-
sign can be a limitation. Yet, the retrospective nature of
this study has four advantages at least. First, we selected
cases with definite diagnosis of bacteremia and severe
complications. Second, we included only the cases with
severe neutropenia, whose median WBC count at FN
onset were 100 /μL. Third, none of the cases had severe
renal dysfunction which interferes to the presepsin
value [17]. Fourth, the measurement of presepsin levels
was made regularly, not in spot, throughout a chemo-
therapy course and FN episode. So we could follow up
the trend from early phase to resolution of bacteremia.
Many of the reports deal with mass data yielded from
hundreds of patients. But detailed understanding and
interpretation of clinical course of every case is also
important.
Conclusion
In conclusion, plasma presepsin level is a reliable marker
of FN even in extremely low WBC counts. In addition to
absolute value, evaluation of increase rate can help early
diagnosis of FN in both myeloid and lymphoid disorders.
Closer monitoring of this molecule could prevent infec-
tion associated death in hematologic malignancy cases.
Additional file
Additional file 1: Table S1. Plasma presepsin level change over time
compared with CRP in FN group (cases 1–11) and AFN group (cases 12–15).
(XLSX 13 kb)
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